ENGENES BIOTECH GMBH

Their core work

ENGENES BIOTECH is a Vienna-based biotechnology SME specializing in protein engineering and synthetic biology, with particular expertise in engineering microorganisms and proteins for industrial applications. Their work spans two complementary tracks: optimizing industrial bioprocesses by exploiting bacterial membrane architecture (lipid rafts), and engineering carbohydrate-binding proteins (lectins) for glycoscience and bioorthogonal chemistry applications. As an industrial partner in academic-led consortia, they translate fundamental synthetic biology insights into manufacturable, process-ready outputs. Their value lies in bridging wet-lab protein engineering with mathematical modeling and systems biology to design microbial chassis that perform reliably at scale.

What they specialise in

How they've shifted over time

In their earlier H2020 engagement (Rafts4Biotech, starting 2017), ENGENES focused on the cell membrane as an engineering substrate — using lipid rafts and spatial cellular confinement to control enzyme localisation and improve industrial bioprocesses, underpinned by systems biology modelling. Their more recent project (synBIOcarb, starting 2018) marks a pivot toward the glycoscience space: the keywords shift to lectins, bioorthogonal ligation, and giant unilamellar vesicles, all pointing to a deepening interest in carbohydrate-binding protein design and chemical biology tools. The through-line is protein engineering, but the application domain has moved from membrane-based bioprocess optimisation toward carbohydrate–protein interaction engineering — a field with growing relevance in diagnostics, drug delivery, and biosensing.

ENGENES appears to be moving deeper into glycobiology and bioorthogonal chemistry, making them an increasingly relevant partner for projects targeting carbohydrate-based therapeutics, biosensors, or cell-surface engineering.

How they like to work

ENGENES has participated exclusively as a consortium member, never as project coordinator, across both its H2020 projects — consistent with a specialist SME that contributes targeted technical expertise rather than project leadership. Despite only two projects, they have accumulated 25 unique partners across 13 countries, which is unusually broad for a two-project portfolio and suggests they joined large, multi-partner RIA and MSCA-ITN consortia. This breadth points to a company that integrates well into academically-led networks as an industrial implementation partner.

With 25 distinct consortium partners spread across 13 countries from just two projects, ENGENES has a disproportionately wide European network for its size. Their participation in an MSCA Innovative Training Network (synBIOcarb) connects them to academic training hubs across multiple EU member states.

What sets them apart

ENGENES sits at a rare intersection: a private SME with genuine wet-lab protein engineering capability that is also fluent in systems biology modelling — a combination more commonly found in academic spin-offs. Their dual fluency in membrane-based synthetic biology and glycoscience means they can serve as the industrial reality-check in consortia that risk staying too theoretical. For a consortium builder, they represent an Austrian biotech voice with hands-on process implementation experience and a demonstrated ability to work inside large, multi-national academic networks.

Highlights from their portfolio

• Rafts4Biotech
  The larger of the two projects (€434,450) and the more industrially oriented — targeting bacterial lipid raft engineering as a platform to co-localise enzymes and boost productivity in real bioprocesses, a concept with direct scale-up potential.
• synBIOcarb
  An MSCA Innovative Training Network focused on lectin and glycoscience protein engineering, placing ENGENES inside a multi-country doctoral training consortium — a strong signal of academic credibility and network depth beyond typical SME involvement.